A5021290996- Breast Cancer Treatment Studies
- Brain Metastases and Treatment
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Glycosylation and Glycoproteins Research
- Breast Lesions and Carcinomas
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Caveolin-1 and cellular processes
- Ovarian cancer diagnosis and treatment
- Breast Implant and Reconstruction
- Galectins and Cancer Biology
- Glioma Diagnosis and Treatment
- Cancer Risks and Factors
- PARP inhibition in cancer therapy
University Hospital of Zurich
2023-2025
University of Zurich
2023-2025
Breast Center
2024
See-Spital
2024
University Medical Center Hamburg-Eppendorf
2014-2023
Universität Hamburg
2014-2023
Klinik und Poliklinik für Neurologie
2016-2023
University Cancer Center Hamburg
2017-2022
Martini-Klinik
2018-2022
Klinik für Frauenheilkunde
2020-2022
Abstract The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety cancer types. In breast cancer, preclinical studies showed that inhibitors the Na + /K ATPase suppress CTC block metastasis. Here we conducted prospective, open-label, proof-of-concept study women metastatic where primary objective was to determine whether treatment inhibitor digoxin could reduce mean cluster size. An analysis nine patients treated daily...
BackgroundWe carried out a prospective clinical study to evaluate the impact of Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).Patients and methodsA total 379 eligible women with estrogen receptor positive (ER+), HER2-negative EBC 0–3 lymph nodes were enrolled. Treatment recommendations, patients' decisional conflict, physicians' confidence before after knowledge RS actual data recorded.ResultsOf 366 assessable patients 244 node negative (N0) 122 (N+)....
<b><i>Introduction:</i></b> Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Cancer provides updated state-of-the-art recommendations for early metastatic breast cancer. <b><i>Methods:</i></b> The evidence-based treatment cancer have been released in March 2024. <b><i>Results Conclusion:</i></b> This...
Abstract The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD‐L1) expression, as quantified by combined positive score (CPS; PD‐L1 expression on both tumour cells and immune cells) in patients previously treated metastatic triple‐negative breast cancer (mTNBC) the phase 3 KEYNOTE‐119 study. This exploratory analysis was conducted to determine whether contributes predictive value CPS mTNBC. samples assessed using IHC 22C3...
Brain metastases (BMs) have a major impact on life expectancy and quality of for many breast cancer patients. Knowledge about treatment patterns outcomes is limited.We analysed clinical data 1712 patients diagnosed with BMs from between January 2000 December 2016 at 80 institutions.Median age diagnosis was 56 years (22-90 years). About 47.8% (n = 732) had HER2-positive, 21.4% 328) triple-negative 30.8% 471) hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The...
The incidence of brain metastases in breast cancer (BCBM) patients is increasing. These have a very poor prognosis, and therefore, identification blood-based biomarkers, such as circulating tumor cells (CTCs), understanding the genomic heterogeneity could help to personalize treatment options. Both EpCAM-dependent (CellSearch® System) EpCAM-independent Ficoll-based density centrifugation methods were used detect CTCs from 57 BCBM patients. DNA individual corresponding primary tumors analyzed...
Abstract Background: Several studies show that the presence of TILs has prognostic significance in TNBC, with greater lymphocytic infiltration associated clinical outcomes. In phase 2 KEYNOTE-086 study, TIL levels were a surrogate marker preexisting antitumor immunity and independent predictors response to pembrolizumab (pembro) monotherapy. Here, we analyzed relationship between outcomes 3 KEYNOTE-119 (NCT02555657) study pembro monotherapy vs single-agent chemotherapy (chemo) patients (pts)...
1013 Background: In the randomized, open-label, phase 3 KEYNOTE-119 study (NCT02555657) , OS was not significantly different with pembro monotherapy versus chemo in second- or third-line settings for mTNBC; however, treatment effect increased increasing PD-L1 enrichment. We evaluated association of TMB efficacy patients previously treated mTNBC. Methods: Patients centrally confirmed TNBC and 1 2 prior systemic treatments metastatic disease were enrolled. randomly assigned 1:1 to 200 mg Q3W...
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents 2024 update evidence-based recommendations for diagnosis and treatment patients with locally advanced metastatic breast cancer.
Alterations in protein glycosylation have been related to malignant transformation and tumour progression. We recently showed that low mRNA levels of Golgi alpha-mannosidase MAN1A1 correlate with poor prognosis breast cancer patients.We analysed the role on a level using western blot analysis (n=105) studied impact MAN1A1-related prognostic relevance adhesion molecules involved microarray data (n=194). Functional consequences mannosidase inhibition inhibitor kifunensine or silencing were...
Dysregulation of lipid metabolism is common in cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been implicated with various cancer types. Here we analyzed by immunohistochemistry its expression 2,197 breast cancers. LPCAT1 staining was found 97.8% 1,774 interpretable tumors, including 48.1% weak, 28.7% moderate, and 14.4% strong expression. The frequency positivity depended on the histological tumor type. Moderate or more cancers no special type (NST) (46.2%) than lobular...